Press releases
- Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update
- Ryvu Therapeutics to present clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress
- Ryvu Therapeutics Presents Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting
- Ryvu Therapeutics Summarizes 2023 Fiscal Year and Provides Corporate Update
Key statistics
As of last trade, Ryvu Therapeutics SA (9Y4:DUS) traded at 12.08, 13.32% above the 52 week low of 10.66 set on May 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 11.98 |
---|---|
High | 12.08 |
Low | 11.98 |
Bid | 12.08 |
Offer | 12.82 |
Previous close | 11.74 |
Average volume | 0.00 |
---|---|
Shares outstanding | 23.12m |
Free float | 14.97m |
P/E (TTM) | -- |
Market cap | 1.25bn PLN |
EPS (TTM) | -4.10 PLN |
Data delayed at least 15 minutes, as of Jun 10 2024 15:31 BST.
More ▼